Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silence Therapeutics plcSLN · Entity 5028 | 10% owner | August 10, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silence Therapeutics plc
Report date August 10, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 7,488,660 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Sale · Acquired 2,792,826 · Balance 7,488,660 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $15.58 | IndirectSee footnote | 7,388,660 |
Reported balance
After 2026-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-10 · Sale · Acquired 100,000 · Balance 7,388,660 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.09 | IndirectSee footnote | 7,338,660 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Sale · Acquired 50,000 · Balance 7,338,660 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.35 | IndirectSee footnote | 7,335,160 |
Reported balance
After 2026-08-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-10 · Sale · Acquired 3,500 · Balance 7,335,160 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 6,535,160 |
Reported balance
After 2026-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-10 · Sale · Acquired 800,000 · Balance 6,535,160 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 6,153,160 |
Reported balance
After 2026-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-10 · Sale · Acquired 382,000 · Balance 6,153,160 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.09 | IndirectSee footnote | 5,682,340 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Sale · Acquired 470,820 · Balance 5,682,340 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 5,077,166 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Sale · Acquired 605,174 · Balance 5,077,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 4,957,166 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Sale · Acquired 120,000 · Balance 4,957,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.35 | IndirectSee footnote | 4,897,166 |
Reported balance
After 2026-08-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-10 · Sale · Acquired 60,000 · Balance 4,897,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 4,797,166 |
Reported balance
After 2026-08-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-10 · Sale · Acquired 100,000 · Balance 4,797,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2025 Filed May 15, 2025 20:51 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 94,234 | Not disclosed Strike: $4.01 | Not disclosed |
DisclosureSEC source: 0001104659-25-049572 · tm2515252-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,065,087 Underlying: Ordinary Shares · 282,702 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 07, 2025 Filed May 8, 2025 11:08 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $3.81 | Not disclosed |
DisclosureSEC source: 0001104659-25-045874 · tm2514463-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,970,853 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 06, 2025 Filed May 8, 2025 11:08 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $3.96 | Not disclosed |
DisclosureSEC source: 0001104659-25-045874 · tm2514463-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,920,850 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 05, 2025 Filed May 8, 2025 11:08 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0001104659-25-045874 · tm2514463-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,820,853 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 01, 2025 Filed May 2, 2025 14:28 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 75,266 | Not disclosed Strike: $3.97 | Not disclosed |
DisclosureSEC source: 0001104659-25-043878 · tm2513902-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,720,853 Underlying: Ordinary Shares · 225,798 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 14:28 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 34,309 | Not disclosed Strike: $3.66 | Not disclosed |
DisclosureSEC source: 0001104659-25-043878 · tm2513902-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,645,587 Underlying: Ordinary Shares · 102,927 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 29, 2025 Filed Apr 30, 2025 11:13 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 54,768 | Not disclosed Strike: $3.49 | Not disclosed |
DisclosureSEC source: 0001104659-25-041787 · tm2513649-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,611,278 Underlying: Ordinary Shares · 164,304 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 11:13 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 95,211 | Not disclosed Strike: $3.43 | Not disclosed |
DisclosureSEC source: 0001104659-25-041787 · tm2513649-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,556,510 Underlying: Ordinary Shares · 285,633 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 25, 2025 Filed Apr 28, 2025 10:50 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 59,568 | Not disclosed Strike: $3.54 | Not disclosed |
DisclosureSEC source: 0001104659-25-039744 · tm2513337-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461,299 Underlying: Ordinary Shares · 178,704 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 10:50 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 90,432 | Not disclosed Strike: $3.42 | Not disclosed |
DisclosureSEC source: 0001104659-25-039744 · tm2513337-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,401,731 Underlying: Ordinary Shares · 271,296 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 23, 2025 Filed Apr 24, 2025 11:16 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $3.18 | Not disclosed |
DisclosureSEC source: 0001104659-25-038340 · tm2513097-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,311,299 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 11:16 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $3.10 | Not disclosed |
DisclosureSEC source: 0001104659-25-038340 · tm2513097-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,261,299 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 21, 2025 Filed Apr 22, 2025 14:35 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $3.12 | Not disclosed |
DisclosureSEC source: 0001104659-25-037215 · tm2512870-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,211,299 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 17, 2025 Filed Apr 22, 2025 14:35 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $3.14 | Not disclosed |
DisclosureSEC source: 0001104659-25-037215 · tm2512870-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,111,299 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 15, 2025 Filed Apr 15, 2025 18:17 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 27,918 | Not disclosed Strike: $2.78 | Not disclosed |
DisclosureSEC source: 0001104659-25-035039 · tm2512383-1_4seq1.xml · derivative · entry 5 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,061,299 Underlying: Ordinary Shares · 83,754 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 18:17 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001104659-25-035039 · tm2512383-1_4seq1.xml · derivative · entry 4 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,033,381 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 18:17 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 40,409 | Not disclosed Strike: $2.71 | Not disclosed |
DisclosureSEC source: 0001104659-25-035039 · tm2512383-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,983,381 Underlying: Ordinary Shares · 121,227 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 18:17 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 56,480 | Not disclosed Strike: $2.33 | Not disclosed |
DisclosureSEC source: 0001104659-25-035039 · tm2512383-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,942,972 Underlying: Ordinary Shares · 169,440 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| April 10, 2025 Filed Apr 15, 2025 18:17 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 25,193 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001104659-25-035039 · tm2512383-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,886,492 Underlying: Ordinary Shares · 75,579 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 14:47 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001104659-25-029715 · tm2510904-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,761,299 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities transactions listed were made by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 11:50 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $2.83 | Not disclosed |
DisclosureSEC source: 0001104659-25-030241 · tm2511054-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,861,299 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities transactions listed were made by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| March 28, 2025 Filed Mar 31, 2025 14:47 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $3.58 | Not disclosed |
DisclosureSEC source: 0001104659-25-029715 · tm2510904-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,661,299 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities transactions listed were made by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 14:47 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $3.32 | Not disclosed |
DisclosureSEC source: 0001104659-25-029715 · tm2510904-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,611,299 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities transactions listed were made by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 16:03 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 22,632 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001104659-25-021245 · tm258471-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,561,299 Underlying: Ordinary Shares · 67,896 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 18, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 60,000 | Not disclosed Strike: $4.85 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 8 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,538,667 Underlying: Ordinary Shares · 180,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| February 13, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 60,000 | Not disclosed Strike: $4.17 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 7 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,478,667 Underlying: Ordinary Shares · 180,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| February 13, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 92,774 | Not disclosed Strike: $4.29 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 6 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,418,667 Underlying: Ordinary Shares · 278,322 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| January 23, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 12,226 | Not disclosed Strike: $5.35 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 5 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,325,893 Underlying: Ordinary Shares · 36,678 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| January 21, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 20,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 4 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,313,667 Underlying: Ordinary Shares · 60,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| January 21, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 25,000 | Not disclosed Strike: $5.20 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,293,667 Underlying: Ordinary Shares · 75,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| January 17, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 150,000 | Not disclosed Strike: $5.35 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Cream Capital Limited Disclosed balance after: 9,268,667 Underlying: Ordinary Shares · 450,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| January 08, 2025 Filed Feb 25, 2025 15:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 30,000 | Not disclosed Strike: $6.48 | Not disclosed |
DisclosureSEC source: 0001104659-25-016802 · tm257556-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,118,667 Underlying: Ordinary Shares · 90,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.